Comparison of clinical profile and outcomes in patients with carbapenem resistant and carbapenem sensitive gram-negative bacteraemia
DOI:
https://doi.org/10.15584/ejcem.2025.4.6Keywords:
antimicrobial stewardship, beta-lactam antibiotics, arbapenem, gram-negative bacteraemiaAbstract
Introduction and aim. Carbapenem-resistant Gram-negative bacteraemia (CR-GNB), an emerging public health concern due to limited treatment options and high mortality rates. Carbapenems, face reduced efficacy against resistant strains, posing a significant challenge. The aim was to compare clinical profiles and outcomes between CR-GNB and carbapenem-sensitive (CS-GNB) and to identify factors influencing mortality among these patients.
Material and methods. This prospective study was conducted at the tertiary care teaching hospital, enrolling 115 patients with GNB (55 CR-GNB and 60 CS-GNB). Following institutional approval and informed consent, patients underwent standardized testing (blood culture and susceptibility testing) with the VITEK method.
Results. CR-GNB patients had significantly longer hospital stays (12.88 vs. 8.87 days, p=0.001), higher ICU admissions (90% vs 49.3%), and prolonged antibiotic use (8.7 vs 6.04 days, p=0.001). Pneumonia was more prevalent in CR-GNB (42.5%) while UTIs dominated in CS-GNB cases (64%). Kaplan-Meier analysis showed increased mortality risk in CR-GNB, with hazard ratios of 1.82 (day-14) and 2.12 (day-28).
Conclusion. Thus, in our study CR-GNB posed a significant hazard for mortality risk. Thus, early identification, stringent infection control measures, and antimicrobial stewardship are crucial and to develop effective treatment strategies tailored to high-risk populations can enhance patient survival and limit the resistance.
Downloads
References
Tsachouridou O, Pilalas D, Nanoudis S, et al. Mortality due to Multidrug-Resistant Gram-Negative Bacteremia in an Endemic Region: No Better than a Toss of a Coin. Microorganisms. 2023;11(7):1711. doi: 10.3390/microorganisms11071711
Kitaya S, Kanamori H, Katori Y, Tokuda K. Impact of Persistent Multidrug-Resistant Gram-Negative Bacteremia on Clinical Outcome and Mortality. Antibiot Basel Switz. 2023;12(2):313. doi: 10.3390/antibiotics12020313
Wen SCH, Ezure Y, Rolley L, et al. Gram-negative neonatal sepsis in low- and lower-middle-income countries and WHO empirical antibiotic recommendations: A systematic review and meta-analysis. PLoS Med. 2021;18(9):e1003787-e1003787. doi: 10.1371/journal.pmed.1003787
Hammour KA, Abu-Farha R, Itani R, et al. The prevalence of Carbapenem Resistance Gram negative pathogens in a Tertiary Teaching Hospital in Jordan. BMC Infect Dis. 2023;23(1):634-634. doi: 10.1186/s12879-023-08610-4
Armstrong T, Fenn SJ, Hardie KR. JMM Profile: Carbapenems: a broad-spectrum antibiotic. J Med Microbiol. 2021;70(12):001462. doi: 10.1099/jmm.0.001462
Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect. 2008;14(12):1102-1111. doi: 10.1111/j.1469-0691.2008.02101.x
Walsh F. Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities. Ther Clin Risk Manag. 2007;3(5):789-794.
Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943-4960. doi: 10.1128/AAC.00296-11
Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15-21. doi: 10.1177/2049936115621709
Cetin S, Dokmetas I, Hamidi AA, et al. Comparison of Risk Factors and Outcomes in Carbapenem-Resistant and Carbapenem-Susceptible Gram-Negative Bacteremia. Sisli Etfal Hastan Tip Bul. 2021;55(3):398-404. doi: 10.14744/SEMB.2020.49002
Eshwarappa M, Gangula RS, Rajashekar R, et al. Clinical, Microbiological Profile, and Treatment Outcomes of Carbapenem-Resistant Urinary Tract Infections in a Tertiary Care Hospital. Indian J Nephrol. 2025;35(1):53-58. doi: 10.25259/ijn_530_23
Han R, Shi Q, Wu S, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. Front Cell Infect Microbiol. 2020;10:314. doi: 10.3389/fcimb.2020.00314
Ishii Y, Eto M, Mano Y, et al. In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2010;54(9):3625-3629. doi: 10.1128/AAC.01397-09
Gomides MDA, Fontes AM de S, Silveira AOSM, et al. The importance of active surveillance of carbapenem-resistant Enterobacterales (CRE) in colonization rates in critically ill patients. PloS One. 2022;17(1):e0262554-e0262554. doi: 10.1371/journal.pone.0262554
Pyakurel S, Ansari M, Kattel S, et al. Prevalence of carbapenemase-producing Klebsiella pneumoniae at a tertiary care hospital in Kathmandu, Nepal. Trop Med Health. 2021;49(1):78-78. doi: 10.1186/s41182-021-00368-2
Tängdén T, Giske CG. Global dissemination of extensively drug‐resistant carbapenemase‐producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med. 2015;277(5):501-512. doi: 10.1111/joim.12342
Theuretzbacher U. Global antimicrobial resistance in Gram-negative pathogens and clinical need. Curr Opin Microbiol. 2017;39:106-112. doi: 10.1016/j.mib.2017.10.028
Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019;69(7):S565-S575. doi: 10.1093/cid/ciz830
Kunjalwar R, Mudey G. A cross sectional study on endemicity of VIM, NDM, KPC, IPM & OXA-48 genes in Carbapenemase producing Klebsiella pneumoniae and Escherichia coli from a tertiary hospital using mCIM, eCIM, and PCR in Central India. F1000Research. 2024;13:636. doi: 10.12688/f1000research.147644.1
Thomas N, Sarwat T. Prevalence of Carbapenem Resistant Enterobacteriaceae in a tertiary care hospital. Int J Curr Microbiol Appl Sci. 2019;8(11):1418-1424. doi: 10.20546/ijcmas.2019.811.166
Hindler JA, Schuetz AN, Clinic M, et al. The CLSI Outreach Working Group (ORWG). 2017;2(1).
Cruz-López F, Martínez-Meléndez A, Morfin-Otero R, et al. Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens. Front Cell Infect Microbiol. 2022;12:884365-884365. doi: 10.3389/fcimb.2022.884365
Aon M, Aoun AH, Al Shami A, et al. Association of Diabetes Mellitus With Increased Mortality in Carbapenem-Resistant Enterobacterales Infections. Cureus. 16(2):e53606. doi: 10.7759/cureus.53606
Ghareeb AM, Raafat MM, Bazan NS, Samir R. Carbapenem-resistant Acinetobacter baumannii infections among diabetic and non-diabetic patients and possible effective combination treatments. Future J Pharm Sci. 2024;10(1):90. doi: 10.1186/s43094-024-00661-x
Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391-400. doi: 10.1016/s1473-3099(18)30099-9
Muteeb G. Network meta-analysis of antibiotic resistance patterns in gram-negative bacterial infections: a comparative study of carbapenems, fluoroquinolones, and aminoglycosides. Front Microbiol. 2023;14:1304011. doi: 10.3389/fmicb.2023.1304011
Hassoun-Kheir N, Hussien K, Karram M, et al. Clinical significance and burden of carbapenem-resistant Enterobacterales (CRE) colonization acquisition in hospitalized patients. Antimicrob Resist Infect Control. 2023;12:129. doi: 10.1186/s13756-023-01323-y
Sharma K, Tak V, Nag VL, et al. An observational study on carbapenem-resistant Enterobacterales (CRE) colonisation and subsequent risk of infection in an adult intensive care unit (ICU) at a tertiary care hospital in India. Infect Prev Pract. 2023;5(4):100312. doi: 10.1016/j.infpip.2023.100312
Priyendu A, Ahmed Z, Nagappa A, et al. Direct costs and length of stay in Carbapenem resistant versus Carbapenem sensitive Klebsiella pneumoniae infections in a tertiary care hospital. Int J Infect Dis. 2016;45:111. doi: 10.1016/j.ijid.2016.02.284
Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024;ciae403. doi: 10.1093/cid/ciae403
Soto CL, Hsu AJ, Lee JH, et al. Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2024;78(1):27-30. doi: 10.1093/cid/ciad476
Park SY, Baek YJ, Kim JH, et al. Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections. Infect Chemother. 2024;56(3):308-328. doi: 10.3947/ic.2024.0038
Nordmann P, Poirel L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019;69(7):S521-S528. doi: 10.1093/cid/ciz824
Afify FA, Shata AH, Aboelnaga N, et al. Emergence of carbapenem resistant gram-negative pathogens with high rate of colistin resistance in Egypt: A cross sectional study to assess resistance trends during the COVID-19 pandemic. J Genet Eng Biotechnol. 2024;22(1):100351. doi: 10.1016/j.jgeb.2024.100351
Cienfuegos-Gallet AV, Ocampo de Los Ríos AM, Sierra Viana P, et al. Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study. BMC Infect Dis. 2019;19:830. doi: 10.1186/s12879-019-4461-x
Kulkova N, Brnova J, Michalikova L, et al. Impact of carbapenem-resistance on 28-days survival in patients with Gram-negative bacteraemia. Int J Infect Dis. 2014;21:96. doi: 10.1016/j.ijid.2014.03.627
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
